Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.
Identifieur interne : 002C66 ( Ncbi/Merge ); précédent : 002C65; suivant : 002C67Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.
Auteurs : Taniawati Supali [Indonésie] ; Yenny Djuardi ; Kenneth M. Pfarr ; Heri Wibowo ; Mark J. Taylor ; Achim Hoerauf ; Jeanine J. Houwing-Duistermaat ; M. Yazdanbakhsh ; Erliyani SartonoSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2008.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Albendazole (effets indésirables), Albendazole (usage thérapeutique), Animaux, Association de médicaments, Brugia malayi (), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Doxycycline (usage thérapeutique), Enfant, Femelle, Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (traitement médicamenteux), Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé.
- MESH :
- effets indésirables : Albendazole, Diéthylcarbamazine, Filaricides.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Doxycycline, Filaricides.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Association de médicaments, Brugia malayi, Enfant, Femelle, Humains, Mâle, Méthode en double aveugle, Résultat thérapeutique, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Albendazole (adverse effects), Albendazole (therapeutic use), Animals, Brugia malayi (drug effects), Child, Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Double-Blind Method, Doxycycline (therapeutic use), Drug Therapy, Combination, Elephantiasis, Filarial (drug therapy), Female, Filaricides (adverse effects), Filaricides (therapeutic use), Humans, Male, Middle Aged, Treatment Outcome.
- MESH :
- chemical , adverse effects : Albendazole, Diethylcarbamazine, Filaricides.
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Doxycycline, Filaricides.
- drug effects : Brugia malayi.
- drug therapy : Elephantiasis, Filarial.
- Adolescent, Adult, Aged, Animals, Child, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Treatment Outcome.
Abstract
The efficacy of doxycycline for treating the causal agent of human lymphatic filariasis, Brugia malayi, is unknown. Standard treatment with diethylcarbamazine-albendazole is associated with adverse reactions. We assessed whether doxycycline alone or in combination with diethylcarbamazine-albendazole would lead to sustained amicrofilaremia and reduced incidence of adverse reactions.
DOI: 10.1086/586753
PubMed: 18419441
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003302
- to stream PubMed, to step Curation: 003302
- to stream PubMed, to step Checkpoint: 003302
Links to Exploration step
pubmed:18419441Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.</title><author><name sortKey="Supali, Taniawati" sort="Supali, Taniawati" uniqKey="Supali T" first="Taniawati" last="Supali">Taniawati Supali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia. taniawati@yahoo.com</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Djuardi, Yenny" sort="Djuardi, Yenny" uniqKey="Djuardi Y" first="Yenny" last="Djuardi">Yenny Djuardi</name></author><author><name sortKey="Pfarr, Kenneth M" sort="Pfarr, Kenneth M" uniqKey="Pfarr K" first="Kenneth M" last="Pfarr">Kenneth M. Pfarr</name></author><author><name sortKey="Wibowo, Heri" sort="Wibowo, Heri" uniqKey="Wibowo H" first="Heri" last="Wibowo">Heri Wibowo</name></author><author><name sortKey="Taylor, Mark J" sort="Taylor, Mark J" uniqKey="Taylor M" first="Mark J" last="Taylor">Mark J. Taylor</name></author><author><name sortKey="Hoerauf, Achim" sort="Hoerauf, Achim" uniqKey="Hoerauf A" first="Achim" last="Hoerauf">Achim Hoerauf</name></author><author><name sortKey="Houwing Duistermaat, Jeanine J" sort="Houwing Duistermaat, Jeanine J" uniqKey="Houwing Duistermaat J" first="Jeanine J" last="Houwing-Duistermaat">Jeanine J. Houwing-Duistermaat</name></author><author><name sortKey="Yazdanbakhsh, M" sort="Yazdanbakhsh, M" uniqKey="Yazdanbakhsh M" first="M" last="Yazdanbakhsh">M. Yazdanbakhsh</name></author><author><name sortKey="Sartono, Erliyani" sort="Sartono, Erliyani" uniqKey="Sartono E" first="Erliyani" last="Sartono">Erliyani Sartono</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18419441</idno><idno type="pmid">18419441</idno><idno type="doi">10.1086/586753</idno><idno type="wicri:Area/PubMed/Corpus">003302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003302</idno><idno type="wicri:Area/PubMed/Curation">003302</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003302</idno><idno type="wicri:Area/PubMed/Checkpoint">003302</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003302</idno><idno type="wicri:Area/Ncbi/Merge">002C66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.</title><author><name sortKey="Supali, Taniawati" sort="Supali, Taniawati" uniqKey="Supali T" first="Taniawati" last="Supali">Taniawati Supali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia. taniawati@yahoo.com</nlm:affiliation><country xml:lang="fr">Indonésie</country><wicri:regionArea>Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta</wicri:regionArea><wicri:noRegion>Jakarta</wicri:noRegion></affiliation></author><author><name sortKey="Djuardi, Yenny" sort="Djuardi, Yenny" uniqKey="Djuardi Y" first="Yenny" last="Djuardi">Yenny Djuardi</name></author><author><name sortKey="Pfarr, Kenneth M" sort="Pfarr, Kenneth M" uniqKey="Pfarr K" first="Kenneth M" last="Pfarr">Kenneth M. Pfarr</name></author><author><name sortKey="Wibowo, Heri" sort="Wibowo, Heri" uniqKey="Wibowo H" first="Heri" last="Wibowo">Heri Wibowo</name></author><author><name sortKey="Taylor, Mark J" sort="Taylor, Mark J" uniqKey="Taylor M" first="Mark J" last="Taylor">Mark J. Taylor</name></author><author><name sortKey="Hoerauf, Achim" sort="Hoerauf, Achim" uniqKey="Hoerauf A" first="Achim" last="Hoerauf">Achim Hoerauf</name></author><author><name sortKey="Houwing Duistermaat, Jeanine J" sort="Houwing Duistermaat, Jeanine J" uniqKey="Houwing Duistermaat J" first="Jeanine J" last="Houwing-Duistermaat">Jeanine J. Houwing-Duistermaat</name></author><author><name sortKey="Yazdanbakhsh, M" sort="Yazdanbakhsh, M" uniqKey="Yazdanbakhsh M" first="M" last="Yazdanbakhsh">M. Yazdanbakhsh</name></author><author><name sortKey="Sartono, Erliyani" sort="Sartono, Erliyani" uniqKey="Sartono E" first="Erliyani" last="Sartono">Erliyani Sartono</name></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Albendazole (adverse effects)</term><term>Albendazole (therapeutic use)</term><term>Animals</term><term>Brugia malayi (drug effects)</term><term>Child</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Double-Blind Method</term><term>Doxycycline (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Female</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Albendazole (effets indésirables)</term><term>Albendazole (usage thérapeutique)</term><term>Animaux</term><term>Association de médicaments</term><term>Brugia malayi ()</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Doxycycline (usage thérapeutique)</term><term>Enfant</term><term>Femelle</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Doxycycline</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brugia malayi</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Doxycycline</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Animals</term><term>Child</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Association de médicaments</term><term>Brugia malayi</term><term>Enfant</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of doxycycline for treating the causal agent of human lymphatic filariasis, Brugia malayi, is unknown. Standard treatment with diethylcarbamazine-albendazole is associated with adverse reactions. We assessed whether doxycycline alone or in combination with diethylcarbamazine-albendazole would lead to sustained amicrofilaremia and reduced incidence of adverse reactions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18419441</PMID><DateCreated><Year>2008</Year><Month>04</Month><Day>18</Day></DateCreated><DateCompleted><Year>2008</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.</ArticleTitle><Pagination><MedlinePgn>1385-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1086/586753</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The efficacy of doxycycline for treating the causal agent of human lymphatic filariasis, Brugia malayi, is unknown. Standard treatment with diethylcarbamazine-albendazole is associated with adverse reactions. We assessed whether doxycycline alone or in combination with diethylcarbamazine-albendazole would lead to sustained amicrofilaremia and reduced incidence of adverse reactions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A double-blind, randomized, placebo-controlled 6-week field trial of doxycycline treatment (100 mg/day) of 161 persons infected with B. malayi was conducted. Four months after receiving doxycycline (n=119) or placebo (n=42), participants received diethylcarbamazine (6 mg/kg) plus albendazole (400 mg) or a matching placebo. Adverse reactions were assessed 48 and 60 h after administration of diethylcarbamazine-albendazole. Treatment efficacy was evaluated at 2, 4, and 12 months after the initial doxycycline treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four months after beginning doxycycline treatment, Wolbachia loads were reduced by 98%. Doxycycline treatment reduced the prevalence of microfilaremia at 2, 4, and 12 months of follow-up (P<.001 for all time points). At the 1-year follow-up, prevalence was reduced by 77% and 87.5% in patients receiving doxycycline alone or doxycycline plus diethylcarbamazine-albendazole, respectively. In contrast, the reduction of microfilaremia in the group receiving placebo doxycycline plus diethylcarbamazine-albendazole was merely 26.7%. Adverse reactions were lowest in the group receiving doxycycline plus placebo diethylcarbamazine-albendazole and highest in the group receiving placebo doxycycline plus diethylcarbamazine-albendazole. The proportion of persons with high fever and severe adverse reactions was significantly reduced in the group treated with doxycycline plus diethylcarbamazine-albendazole.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A 6-week course of doxycycline, either alone or in combination with diethylcarbamazine-albendazole, leads to a decrease in microfilaremia and reduces adverse reactions to antifilarial treatment in B. malayi-infected persons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Supali</LastName><ForeName>Taniawati</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Parasitology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia. taniawati@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Djuardi</LastName><ForeName>Yenny</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Pfarr</LastName><ForeName>Kenneth M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Wibowo</LastName><ForeName>Heri</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hoerauf</LastName><ForeName>Achim</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Houwing-Duistermaat</LastName><ForeName>Jeanine J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Yazdanbakhsh</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sartono</LastName><ForeName>Erliyani</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2017 Feb 1;542(7639):7</RefSource><PMID Version="1">28150793</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017178" MajorTopicYN="N">Brugia malayi</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18419441</ArticleId><ArticleId IdType="doi">10.1086/586753</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Indonésie</li></country></list><tree><noCountry><name sortKey="Djuardi, Yenny" sort="Djuardi, Yenny" uniqKey="Djuardi Y" first="Yenny" last="Djuardi">Yenny Djuardi</name><name sortKey="Hoerauf, Achim" sort="Hoerauf, Achim" uniqKey="Hoerauf A" first="Achim" last="Hoerauf">Achim Hoerauf</name><name sortKey="Houwing Duistermaat, Jeanine J" sort="Houwing Duistermaat, Jeanine J" uniqKey="Houwing Duistermaat J" first="Jeanine J" last="Houwing-Duistermaat">Jeanine J. Houwing-Duistermaat</name><name sortKey="Pfarr, Kenneth M" sort="Pfarr, Kenneth M" uniqKey="Pfarr K" first="Kenneth M" last="Pfarr">Kenneth M. Pfarr</name><name sortKey="Sartono, Erliyani" sort="Sartono, Erliyani" uniqKey="Sartono E" first="Erliyani" last="Sartono">Erliyani Sartono</name><name sortKey="Taylor, Mark J" sort="Taylor, Mark J" uniqKey="Taylor M" first="Mark J" last="Taylor">Mark J. Taylor</name><name sortKey="Wibowo, Heri" sort="Wibowo, Heri" uniqKey="Wibowo H" first="Heri" last="Wibowo">Heri Wibowo</name><name sortKey="Yazdanbakhsh, M" sort="Yazdanbakhsh, M" uniqKey="Yazdanbakhsh M" first="M" last="Yazdanbakhsh">M. Yazdanbakhsh</name></noCountry><country name="Indonésie"><noRegion><name sortKey="Supali, Taniawati" sort="Supali, Taniawati" uniqKey="Supali T" first="Taniawati" last="Supali">Taniawati Supali</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002C66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:18419441
|texte= Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:18419441" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |